JP2022536092A5 - - Google Patents

Info

Publication number
JP2022536092A5
JP2022536092A5 JP2021571989A JP2021571989A JP2022536092A5 JP 2022536092 A5 JP2022536092 A5 JP 2022536092A5 JP 2021571989 A JP2021571989 A JP 2021571989A JP 2021571989 A JP2021571989 A JP 2021571989A JP 2022536092 A5 JP2022536092 A5 JP 2022536092A5
Authority
JP
Japan
Prior art keywords
inhibitors
antibodies
mmol
pyrimidine
uplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571989A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595593B2 (ja
JP2022536092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000559 external-priority patent/WO2020245664A1/en
Publication of JP2022536092A publication Critical patent/JP2022536092A/ja
Publication of JP2022536092A5 publication Critical patent/JP2022536092A5/ja
Application granted granted Critical
Publication of JP7595593B2 publication Critical patent/JP7595593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571989A 2019-06-04 2020-06-04 増殖性疾患の治療のための、ヒトctps1阻害剤としてのn-(5-(6-エトキシピラジン-2-イル)ピリジン-2-イル)-4-(2-(メチルスルホンアミド)ピリミジン-4-イル)テトラヒドロ-2h-ピラン-4-カルボキサミド誘導体及び関連化合物 Active JP7595593B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19305713 2019-06-04
EP19305713.0 2019-06-04
EP19306144 2019-09-20
EP19306144.7 2019-09-20
PCT/IB2020/000559 WO2020245664A1 (en) 2019-06-04 2020-06-04 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
JP2022536092A JP2022536092A (ja) 2022-08-12
JP2022536092A5 true JP2022536092A5 (cg-RX-API-DMAC7.html) 2023-06-23
JP7595593B2 JP7595593B2 (ja) 2024-12-06

Family

ID=71895028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571989A Active JP7595593B2 (ja) 2019-06-04 2020-06-04 増殖性疾患の治療のための、ヒトctps1阻害剤としてのn-(5-(6-エトキシピラジン-2-イル)ピリジン-2-イル)-4-(2-(メチルスルホンアミド)ピリミジン-4-イル)テトラヒドロ-2h-ピラン-4-カルボキサミド誘導体及び関連化合物

Country Status (10)

Country Link
US (2) US12466810B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980411B1 (cg-RX-API-DMAC7.html)
JP (1) JP7595593B2 (cg-RX-API-DMAC7.html)
CN (1) CN114008039B (cg-RX-API-DMAC7.html)
DK (1) DK3980411T3 (cg-RX-API-DMAC7.html)
ES (1) ES3044436T3 (cg-RX-API-DMAC7.html)
FI (1) FI3980411T3 (cg-RX-API-DMAC7.html)
HU (1) HUE073329T2 (cg-RX-API-DMAC7.html)
IL (1) IL288508B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020245664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2022165404A1 (en) * 2021-02-01 2022-08-04 University Of Southern California Enzyme inhibitors and viral infection therapy
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
CA3244038A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
CN118359588A (zh) * 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物
WO2026027753A1 (en) * 2024-08-02 2026-02-05 Step Pharma S.A.S. Ctps1 inhibitors for the treatment of myeloproliferative neoplasms

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523882A (en) 2000-08-21 2004-11-26 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
US7091201B2 (en) 2000-09-25 2006-08-15 Actelion Pharmaceuticals Ltd. Arylalkane-sulfonamides having endothelin-antagonist activity
US20030158218A1 (en) 2001-12-21 2003-08-21 Nantermet Philippe G. Thrombin inhibitors
ES2325836T3 (es) 2004-07-26 2009-09-21 Merck Serono Sa Derivados de la n.hidroxiamida y uso de los mismos.
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
JP2011506445A (ja) 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
KR101097312B1 (ko) 2009-08-10 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
JP5938038B2 (ja) * 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
WO2012068343A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
JP2016028795A (ja) 2013-03-28 2016-03-03 国立研究開発法人科学技術振興機構 触媒金属ナノ粒子含有複合体及びその利用
JP2016523818A (ja) 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるt細胞増殖を阻害するための方法及び医薬組成物(ctps1阻害剤、例えばノルロイシン)
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
GB201322333D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res WNT pathway modulators
SMT201900615T1 (it) 2014-10-08 2020-01-14 Redx Pharma Plc Derivati di acetammide n-piridinile come inibitori del percorso di segnalazione wnt
CN104262071A (zh) 2014-10-16 2015-01-07 中国科学院山西煤炭化学研究所 一种联苯类化合物的光催化合成方法
EP3492454A1 (en) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
AU2018413791B2 (en) 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
US20230192673A1 (en) 2018-06-04 2023-06-22 Step Pharma S.A.S. Compounds
PL3870574T3 (pl) 2018-10-23 2023-05-02 Step Pharma S.A.S. Pochodne aminopirymidyny/pirazyny jako inhibitory CTPS1
WO2020245665A1 (en) 2019-06-04 2020-12-10 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
US20230020663A1 (en) 2019-09-20 2023-01-19 Step Pharma S.A.S. Sulfonamide inhibitors as ctps1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
CA3244038A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
US20250270200A1 (en) 2022-04-21 2025-08-28 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
CN118359588A (zh) 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物

Similar Documents

Publication Publication Date Title
CN114761398B (zh) 杂环rip1激酶抑制剂
US12297203B2 (en) Pyrrolopyrimidine ITK inhibitors
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
WO2025123007A1 (en) Ras inhibitors and methods of use thereof
CA2906157C (en) Highly active anti-neoplastic and anti-proliferative agents
JP6561128B2 (ja) Cns疾患を治療するための縮合ジヒドロ−4h−ピラゾロ[5,1−c][1,4]オキサジニル化合物およびアナログ
DK3191477T3 (en) USEFUL CONDENSED BICYCLEIC (HETERO) AROMATIC COMPOUNDS IN CANCER TREATMENT
CN112368278A (zh) Rip1抑制性化合物以及制备和使用其的方法
AU2014368992B2 (en) Tetrahydropyridopyrazines modulators of GPR6
WO2019090158A9 (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
CA3149729A1 (en) Rip1 inhibitory compounds and methods for making and using the same
CN114206339A (zh) 氘化mk2途径抑制剂及其使用方法
EP3383386A1 (en) Modulators of chemokine receptors
WO2020210379A1 (en) Phosphatidylinositol 3-kinase inhibitors
WO2015189620A1 (en) Pyrazolopyrimidine derivatives useful as inhibitors of bruton's tyrosine kinase
CA3188752A1 (en) Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection
AU2021300831A1 (en) RIP1k inhibitors
JP2023539336A (ja) Gpr52モジュレーター化合物
HK40082783A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40006461A (en) Process for the preparation of fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds
NZ787918A (en) Pyridopyrimdinone CDK2/4/6 inhibitors
HK40073618B (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
HK40073618A (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders